Q3 2022 Pfizer Inc Earnings Call
Good day, everyone and welcome to Pfizer's third quarter 2022 earnings Conference call.
Today's call is being recorded.
At this time I would like to turn the call over to Mr. Christie, Though senior Vice President and Chief Investor Relations Officer. Please go ahead Sir.
Let's see.
Good morning, welcome to Pfizer's third quarter earnings call. We anticipate that this call will last 60 minutes.
Joining today by Dr. Albert boiler, our chairman and CEO , Dave Denton our CFO .
Dr. Michael Goldstein, President of worldwide research and development in medical Joy.
Joining for the Q&A session. We will also have Angela Kang Chief commercial officer, and President of Global Biopharmaceutical business I mean, your Malik our chief business Innovation Officer, Dr. William Powell, our Chief Development Officer, and Doug length, or our general counsel.
Before we begin the call I'm also happy to announce that we will host an analyst day in New York City on the afternoon of December 12.
Members of our executive team and other leaders that Pfizer will share information on a rich slate of potential near term product launches and the R&D Readouts, which will drive the next wave of product launches after that.
Both of which will support our 2030 revenues and beyond.
In person attendance will be by invitation.
We will also be webcasting the event.
Could you talk more about the agenda today, we look forward to providing more details as we get closer to December 12.
Materials for this call and in other earnings related materials on the Investor Relations section of Pfizer Dot com.
Please see our forward looking statements disclaimer on slide four and additional information regarding these statements and our non-GAAP financial measures is available in our earnings release.
And in our SEC forms 10-K, and 10-Q under risk factors and forward looking information and factors that may affect future results.
Looking statements on the call are subject to substantial risks and uncertainties and speak only as of the calls original date and we undertake no obligation to update or revise any of these statements with that I will turn the call over to Albert.
Thank you, Chris Hello, everyone and thank you for joining us today.
I will briefly touch on some recent highlights I will then spend the bulk of my time speaking to our expectations for what we feel would be a promising and prosperous future for Pfizer and the patients we serve.
In addition to generating stellar financial performance.
Since our last earnings call, we reported positive data for several exciting pipeline programs, including our RSV vaccine candidate for older adults.
24 children, the potential combination treatment of zima.
Expand the in men with metastatic castration resistant prostate cancer, our pentavalent Meningococcal vaccine candidate for adolescence and young adults.
We're less exciting progress all four of our <unk> one program in type two diabetes and obesity.
Okay.
We announced positive top line data from the phase III clinical trial investigating a bivalent RSV vaccine candidate.
Mr. Redman participants to help protect their infants from RSV disease after birth.
We established a new commercial structure within our global biopharmaceutical business that is focused on three broad therapeutic areas, Brian Margaret, especially don't take care and oncology will.
We believe this new structure will enable us to maximize the commercial success of the multiple exciting product launches, including several potential blockbusters.
Poised to emerge from our scientific pipeline over the next few years.
We have continued to advance potentially game changing vaccines in the fight against the respiratory disease by entering into a phase III study for mrna flu vaccine candidates and initiating a phase III study for a vaccine candidate that combines our MMA flu and COVID-19 vaccine in one short.
We completed the acquisitions of bio Kevin Pharmaceuticals, and global blood.
Blood therapeutics, giving us market, leading franchises in both migraine and sickle cell disease, respectively.
Less than six months ago after launching and of course for our currently awarded breakthrough initiatives designed to close the equity gap for one 2 billion people living in 45 lower income countries I'm proud to say that the first shipments of our products have arrived to these countries and we are working with.
So on the credit system improvements that can make sure. These products reached those needs.
And of course, we continue to lead the fight against COVID-19, most notably our omicron adapted bivalent COVID-19 vaccine has been authorized by the U S food and drug administration.
The European Medicines agency and several other regulatory bodies and as part of Pfizer's commitment to providing equitable access to COVID-19 oral treatments, we agreed to supply at the non for profit price up two 6 million Bucks probably to treatment courses to the global fund for low and lower middle income comes.
Yes.
An exciting quarter for sure.
But in our company and our industry, it's all about what's next.
Next breakthrough medicine or vaccine.
Our next game changing technology, the next solution to an unmet patient need.
This continued pursuit of what's next is embedded in pfizer's DMA in the foundational driver of our purpose breakthroughs.
Breakthroughs, but could change based on slides. It's also why we have confidence that Pfizer story is a story of growth.
We recognize that some are questioning pfizer's long term growth prospects, particularly in the 25% to 30 timeframe.
That's understandable given that we currently expect the negative impact of approximately $17 billion in revenues from the losses of exclusivity during that period based on our internal calculation.
We believe we.
We not only can overcome these expected declines, but also can potentially generate strong growth through the end of the decade.
Let's take a closer look on how we expect to accomplish this.
Our strong capital position has given us the ability to pursue business development opportunities with the potential if successful of course.
At least 25 billion.
Risk adjusted revenues through our 2030 top line expectation.
We believe the deals we have already done four arena <unk> global blood Therapeutics, and revival pivotal potential to get us more than one third.
Over the way there.
And that we have more than enough capital to invest in the additional opportunities needed to meet or exceed these targets.
Perhaps even more exciting is the wave of potential.
Growth drivers emerging from our R&D pipeline in the knee.
Near term.
Over the next 18 months, we expect to have up to 19, new products or indications in the market, including the five for which we have already begun profile Muslims co promotions off commercial organization earlier this year.
We can find you can find at least.
<unk> launches in the appendix of the presentation, we posted today for this earnings growth.
If successful these 19 launches of which more than two thirds have the potential to be blockbusters would be the most ever in <unk> history.
This is in house developed projects alone.
Potentially represent approximately $20 billion in 'twenty therapy sales.
With more than offset the expected impact.
Many of these programs are already largely derisked from a clinical perspective.
The majority of them were discovered in house and nearly all of them would be for indications outside of COVID-19.
If approved we expect each of these to be key contributors to our growth aspirations through 2025 and beyond.
And of course with minimal potential vaccines and medicines in our pipeline with numerous launches expected in the 24 timeline.
These include gene therapy candidates for hemophilia B in Duchenne muscular dystrophy.
Our oral <unk>, one for diabetes and obesity, a potential combo vaccines that would cover fluent Kobe in one saw and mainly minimal.
With regards to our COVID-19 programs, while their sales may fall from our expected 2022.
Rules of approximately combined 65 billion, we believe our COVID-19 franchises will remain multi billion dollar revenue generators for the foreseeable future.
Which should serve as a buffer for any unforeseen challenges with other products in our portfolio.
Our confidence to execute this plan.
Stems from.
The depth of our financial resources.
The firepower it gives us to pursue business development opportunities.
The power brand equity, we have built up over the past 170 years and further enhance.
In the past two years.
According to a recent survey our brand awareness now stands at an impressive eight 2%.
And our favor ability stands at 61% compared with 42% for the industry as a whole results that were obtained just couple of months ago.
And of course, the strength of the three foundational pillars of our company our World class scientific.
Our world class commercial.
Our world class manufacturing engines and Youll see in this slide some highlights of each one of them.
Let me now briefly highlight three potential blockbusters that we expect to contribute to our long term growth.
RSV scenario, a significant unmet need, particularly in older adults and the influence each year its estimated more than.
77000 older adults are hospitalized and 14000 of them.
In the U S alone due to RSV.
But as confirmed by a diagnostic test we believe we have the potential to be a leader in this space.
Real impact on public health.
On March 24 of this year, the FDA granted breakthrough designation for our RSV vaccine candidate for the prevention of lower respiratory tract disease caused by RSV individuals 60 years of age or older. We are excited to report positive top line data from the phase III trial in late August where there isn't present.
Patients will be the <unk> results.
'twenty two.
A preplanned interim analysis.
So vaccine efficacy of 67% against that as we are associated with lower respiratory tract illness defined by two or more symptoms and vaccine efficacy.
85, 7% was observed in participants with more severe disease, presenting three or more RSV associated symptoms of lower respiratory tract illness.
We are also excited about the potential for our maternal RSV vaccine candidate.
Globally, the year out as we speak and is more than 6 million infants under six months old and <unk> approximately $45.
As announced this morning, our maternal RSV study met this success to our theater in for one of the two primary endpoints vaccine efficacy of 81, 8% was observed against severe medically attended lower respiratory tract illness due to RSV.
In infants from birth through the first 90 days of life and high efficacy of 69, 4% was demonstrated through the first six months of life.
So there is a potential debt subject to regulatory approval by late 2023 early 2020 before we can have the only RSV maternal vaccine on the market along with and not as a vaccine for older adults as high efficacy entities, well tolerated with no safety concerns.
Combined the two indications represent a potential multi billion dollar.
Revenue opportunity if approved especially with our highly respected primary care sales force executing these loans.
Including the RSV antiviral investigational candidates, we acquired with the revival we aim to have end to end solutions with both preventative vaccines and therapeutics to treat those infected with RSV.
In terms of go lives in or you will see is economy is a chronic and often debilitating inflammatory bowel disease that affects an estimated 1 million people in the U S alone.
Many patients living with this disease never achieve or maintain remission and physicians are seeking effective proven oral therapies with a favorable benefit risk profile that can be an attractive first line advanced therapy option.
As a result, we expect the market opportunity to grow by about 50% over the next five years.
The positive phase III data from the elevate UC 12, and 52 trials reinforce our belief that attraction with a differentiated clinical profile and can be an important treatment option.
If approved.
We believe that addressing what can be a multi billion dollar blockbuster program.
We expect to launch the product in the U S. As soon as the second half of 2023 pending regulatory approval.
Through our specialty care sales force, which already has strong relationships in the UC market. Thanks to its work with Xeljanz by a singular et cetera.
Lastly.
Let's look at migraine.
Following our acquisition of Bai are having in Amdocs dopa, we're now aiming to build the world's leading global migraine franchise with the potential to impact 1 billion patients around the world.
<unk> is a debilitating disease and 11, 6% prevalence worldwide.
In the U S alone there are 40 million patients with migraine.
One out of five women are migraine sufferers right now.
The economic burden is significant.
76 billion per year.
We believe our portfolio, including nuclear <unk>, <unk> and as I visit product.
Good to meet a range of needs in the market.
Allowing physicians and patients to decide how to appropriately <unk> migraine treatment and prevention.
As a result, we see the potential to reach more than $6 billion in peak revenues.
Together altogether in the U S notebook is growing very well, including the impact of Pfizer's corporate marketing, which began in August pre close Nerf <unk> has further strengthened its number one market share position to the oral since ERP market and we expect even stronger.
Growth as we deliver on our promise to further enhance our commercial efforts behind this program.
Outside the U S because being approved in the EU UK Israel Kuwait.
The United Arab Emirates, and we have filed for registration in an additional 10 markets.
<unk>. This is not a new product launch. We believe this is a great example of how we can take this portfolio to new heights by leveraging the full strength of Pfizer's Global convention and including in primary care physicians.
Moving over to <unk>.
We recently expect to launch <unk> intranasal in the U S next year pending FDA approval and we plan to globally commercialize.
Lastly, the Oro.
Prevention Phase III trial is ongoing with data readouts expected in the third quarter.
So with that I'll turn it over to Dave to update you on the results and outlook for the financials after Dave Michael will speak about the progression of our pipeline.
Thank you Albert and good morning, I'll begin this morning with a few comments regarding how the company continues to deploy capital in a disciplined manner in support of long term growth and importantly enhanced shareholder returns.
As you know pfizer's cash generation capabilities habits has expanded significantly over the past several years and the efficient deployment of this capital is more critical than ever.
During the first nine months of 2022, the company has deployed and committed capital in three main areas.
First we've invested $7 8 billion in internal R&D as we continue to support our growing pipeline of innovative medicines. These.
These investments are squarely focused on driving revenue growth through 2030.
Secondly in the first three quarters of this year, we have invested approximately $8 billion.
<unk> completed business transactions.
Additionally, early in the fourth quarter, the company completed investments of more than $18 billion in transactions, including both bio Haven in GBT, which brings us to approximately 26 billion in capital deployed for business development transactions, thus far in 2022 alone.
These transactions illustrate our progress towards the goal of adding 25 billion and risk adjusted adjusted 2030 revenues through BD.
And finally, we have returned nearly $9 billion of capital through to shareholders through a combination of both dividends and value enhancing share repurchases.
Clearly maximizing shareholder value through prudent capital allocation will continue to be a major focus for Pfizer.
So with a lag with that.
Let me briefly review our financial results for the quarter.
I'll limit my remarks, largely to adjusted and operating growth figures.
Third quarter revenues demonstrated strength across many areas of the business, but much of that strength was somewhat obscured by our incredibly strong performance in the third quarter of 2021.
Given the strength in the prior year revenues this quarter decreased 2% operationally however.
However, looking at it on a two year basis revenues this quarter were up more than 120% compared to the third quarter of 2020.
The slight decrease compared to last year was in line with our expectation expectations given the phasing of scheduled delivery deliveries of commodity, which we discussed in our earnings call last quarter.
Also underlying our results. This quarter was the strong performance of Pac slowly as well as continued strength from a number of our other key products.
Excluding direct sales in alliance revenues related to the Covid products Pfizer's revenues grew 2% operationally in the quarter.
Gross margins expanded by 4500 50 basis points versus the third quarter of L. Y. This improvement is largely due to increased sales of higher margin <unk> and decreased sales of lower gross margin commodity compared to last year.
Improvements were partially offset by the impact of a $400 million charge related to excess raw materials materials for <unk>.
Given the unpredictable nature of the buyers we intentionally chose to order additional stock to ensure we can meet any global health demand if an extreme need were to arise.
Adjusted <unk> expenses in the third quarter grew 23% operationally the.
The increase was primarily driven by spending for <unk>, and <unk> and higher healthcare reform fees.
The 2% operational increase in adjusted R&D expense in Q3 was primarily driven by increased costs to develop recently acquired assets as well as investments for certain oncology and non COVID-19 vaccines programs.
This was partially offset by lower spending on programs to prevent and treat COVID-19, and various late stage clinical programs.
The effective tax rate on adjusted income in the quarter was four 4%.
Significantly lower than typical driven by tax benefits related to global income tax resolutions and multiple tax.
Jurisdictions spanning several tax years.
Excluding these tax resolutions the underlying tax rate was consistent with historical trends.
As a result reported diluted earnings per share of $1 51 group.
<unk> grew by 6%.
While adjusted diluted earnings per share of $1 78 grew 44% on an operational basis in the quarter.
Foreign exchange movements continued to dampen our results negatively impacting revenues by approximately $950 million and adjusted diluted earnings per share by five <unk> this quarter.
Now let me, let me move to our updated 2022 guidance.
Given our strong third quarter performance and our improving outlook for the year we are in.
Increasing our operational expectations for revenues by one 7 billion.
And adjusted diluted earnings per share by <unk> 19.
This operational increase on the bottom line would have been even higher if not for an incremental <unk> <unk> negative impact due to higher acquired IP R&D expenses.
Partially offsetting these operational increases is the impact of additional strengthening of the U S. Dollar since we last updated guidance in late July .
Incremental foreign exchange movements negatively impacted our expectations for 2022 revenues and adjusted diluted earnings per share by $700 million.
And nine respectively.
The net impact of these cross currents result in increases to the mid points of our revenue and adjusted diluted earnings per share guidance ranges each.
These revised ranges reflect operational growth rates of 31% for revenues.
70% for adjusted diluted earnings per share at the midpoint.
Compared to 2021, and this is up from our previous operational growth expectations for revenues and adjusted diluted earnings per share up 29% and 65% respectively.
Regarding our COVID-19 related revenues, we now expect the vaccine revenue for the year to be approximately $34 billion.
Up by $2 billion compared to our prior guidance.
Four pack slow, but we expect sales of approximately $22 billion, keeping the guidance range unchanged. Despite the negative incremental impact of changes in FX.
You can see on this slide that our updated cost and expense guidance, which incorporates our performance to date, our recent acquisitions and our updated expectations for remainder of the year.
More information on each of these updates can be found in this morning's press release.
2022 guidance once again assumes no incremental share repurchases beyond the $2 billion of share repurchases. We completed in March 2022.
In closing this is exciting time in the history of Pfizer, we believe that our strong financial performance in the quarter and our improving operational outlook for the year sets the stage for long term shareholder value creation.
With that I'll now turn it over to Michael.
Thank you Dave today, I Wouldnt focus attention on high value programs that will potentially deliver breakthroughs in areas of high unmet need and are expected to be key contributors to our growth aspirations through 2025 and beyond.
With anchor products, such as commodity pecs levied IP brands and extend <unk>. We are building out comprehensive patent cases in several areas, including respiratory metabolic disorders unit became apology and certain cancers.
We have deep expertise in these areas and there is exciting science <unk> I.
I will share updates on from three of these today respiratory metabolic and prostate cancer.
Building on our success with <unk>, we see enormous potential to help address major causes of respiratory disease through vaccines and therapeutics work on the next generation vaccine candidates are well underway and last week, we started a phase one clinical trial of our second generation.
All run therapeutic candidates.
Our quadrivalent model in a flu program has progressed into phase III.
And we will start the phase one study of mrna based vaccine candidate that combines our quadrivalent model RNA flu vaccine candidate with the Omicron adapted bivalent COVID-19 vaccine based on <unk> slide five.
In RSV, we believe a dual focus on developing a vaccine and antivirals could make a significant impact globally I will show new data with you shortly.
Texas continues to be an important tool in helping to combat the impact of COVID-19, and secondary endpoints from the epic high risk study as well as data from real world evidence support the product's efficacy profile.
In the epic HR studies, Pecs Levine reduced COVID-19 related all cause deaths and ICU admissions by 100% and.
And COVID-19 related hospitalization by 86% in unvaccinated high risk patients compared to placebo.
It also reduced the duration of COVID-19 symptoms, but two to three days compared to placebo.
Pleased to see pectin with leading the COVID-19 treatment landscape and remain confident in its safety and efficacy in treating patients and high risk with severe outcomes.
We recently reported a positive interim analysis from our phase III studies in older adults of our novel RSV vaccine candidate.
Which targets the pre fusion protein on both or is the ANP without need for an adjuvant, we saw remarkable vaccine efficacy across deposit or is the seasonal.
The vaccine was extremely well tolerated with favorable systemic tolerability.
Key consideration for vaccines.
We are also developing the RSV progress.
<unk> candidate for use in pregnant women.
That protection may be conferred to newborns and this morning, we.
Most exciting results from a pre planned interim analysis of our phase III trial.
We observed a vaccine efficacy of nearly 82% against severe medical attended lower respiratory tract illness, or MAA and RTI due to RSV in infants from birth through the first 90 days of life.
And the efficacy of more than 69% through the first six months of life.
<unk> was not met for the second primary end point will have a clinically meaningful efficacy was observed with M. I <unk>, 57% in infant from Bud through 90 days of life and the efficacy of 51% over the six months follow up period.
The data monitoring committee indicate that the vaccine was well tolerated with no safety concerns with either vaccinated women order new bonds.
Given these impressive returns we look forward to filing BLA for both older adults and pregnant women with the U S. FDA by year end with potential launches in 'twenty three if approved.
Sure Matt Tunnel RSV vaccine candidate potentially would be the first available to help prevent this common and potentially life threatening respiratory illness in young infants.
Turning now to prostate cancer, we are building upon the standard of care set by extending in castration sensitive in castration resistant population.
Phase III embark study or extend the non metastatic castration sensitive prostate cancer is expected to read out first half of 2003.
And the phase III Tal approved three study of <unk> and <unk> is expecting 24. These.
These trials may indicate benefit in up to 20% more patients than are currently treated and potentially prolonged duration of use subject to clinical success and regulatory approval now Intel approved to reabsorb. The first clinical benefit of a PARP inhibitor.
Plus extending in men with metastatic castration resistant prostate cancer with or without homologous recombination repair or H R. R gene mutation.
Irrespective of H R gene mutation stages. The study achieved its primary endpoint the combination delivered a significant and clinically meaningful improvement in radiographic progression free survival.
And appears to have resulted in the longest books.
In a randomized trial in this setting we are encouraged by these results and believe that <unk> in prostate cancer, you have blockbuster potential subject to regulatory approval.
Turning to metabolic disorders.
I have previously said that we are developing two oral blip, one receptor equities down a glib prone and 15 32.
Recently presented phase one data for <unk> 32 showed dose dependent reduction from baseline at four to six weeks mean daily glucose.
Fasting plasma glucose HBA, when CE and body weight.
Both candidates are potentially best in class.
And differentiated by offering full equities.
Which may be required to achieve the same level of response is injectable <unk> one receptor agonist, while offering a convenient once daily dose for <unk> 32.
Glucose effects plateau with lower doses, while bodyweight effect continue to.
Improve at higher doses.
The planned phase II study will evaluate <unk> 32 versus both <unk> and placebo in type two diabetes and separately versus placebo in obesity.
Using similar good tied as a comparison to.
<unk> should allow us to absorb potential early signs of differentiation in efficacy Tolerability and safety.
We will evaluate doses up to 260 milligram in this study higher than the studies.
The phase one b.
We plan to begin dosing soon and anticipate the readout in first quarter 2020 for the ongoing phase two <unk> study, we've done a glib pruning obesity. We know once monthly titration is expected to complete the second half of 2023.
Data from these studies will be available in relatively quick succession, and assuming clinical success allow us to select one based on efficacy tolerability and dosing to advance to phase III in both type two diabetes and obesity.
In closing we are excited about the developing science within these franchisees and surety of recent and anticipated milestones in the next 18 months. We look forward to continued our development work for potential patient benefit and sustainable growth. Thank you let me touch.
<unk> decreased to start Q&A.
Thanks, Michael with that let's start the Q&A session. We have about 30 minutes for this session. We will answer as many questions as time permits and Investor relations will be available after the call to answer any follow up questions. Chelsea. Please go ahead and queue up the first question.
Thank you Sir at this time, if you would like to ask a question. Please press the star and one Keith on your Touchtone phone.
If you find that your question has been addressed you may remove yourself from the queue at any time by pressing star Q.
Once again that is star one to ask a quick question and we'll pause for a brief moment to allow questions to queue.
Our first question will come from Barbara <unk> with Evercore ISI. Your line is open.
So on a go ahead sorry.
Tom are you there.
Your line is open please make sure you are not muted.
Maybe we should we will go to IDEXX question.
Colin Bristow with UBS Your line is open.
Hey, good morning, Thanks for taking the question.
In 2020 expectation should we expect anything from you here on the December 12, Investor event, and then just more broadly around this how are you thinking conceptually about guiding to this would it be similar to last year and you're thinking of growth of the scenario I think guiding.
Anything that would be helpful. And then just a sort of a temperature check on business development.
If you could update us on your priorities and interests and then from a deal perspective, how big would you be willing to go. Thank you.
Thank you.
Remember 12, what you should expect it is a good overview of our very important new product launches in the coming 18 months with more details about the science and the market potential of those lenses as well as some of the most important pipeline potential new medicines.
<unk>, but they're not going to be launched in the next 18 months will be launched in the period between 2014 <unk>.
Now for the BD priorities I would ask Amir to.
I'll reiterate once more our strategy when it comes to BD. Thanks for the question Tom.
<unk> priorities remain consistent with what we've articulated before us and principally we are most excited about scientific substrate that has the potential for patient breakthroughs, that's going to continue to be our north star.
We're looking for deals that accelerate our topline growth in the back half of the decade, and importantly, we're focused on opportunities, where we can add substantial value and that can come in the form of either shaping the science are also accelerating our commercial momentum and if you look at the deals that we announced and closed in 2022, including arena buyout.
Hey, Ben <unk>, they would all be very consistent with those priorities.
We've said that we are agnostic to size of transaction, but you've also heard us be very clear about the fact that cost synergy driven deals is not where our focus is going to be we're going to be focused on driving growth through our BD. Thank.
Thank you Jeremy and also Dave maybe you can also address the question about the guide.
Guidance on corporate and are we going to provide it and win for 'twenty three et cetera, yes. Thank you Albert and maybe let me set the stage as it relates to Covid in the Cobot franchise I think if you look out longer term the franchise is going to be a multibillion dollar franchise in the respect that this is going to be.
Somewhat like a flu sustained flu, but actually more deadly than the flu. So therefore, I think the products both from a vaccine and therapy perspective that Pfizer's has developed are going to be quite relevant for many years to come having said that when we provide guidance for 2023, when it's appropriate to do so we will give it.
Investors a perspective on what our expectations are for the year, we will break out that guidance. Specifically, so you can hold us accountable for delivering on those revenue promises when the time comes.
Thank you Mexico. Please.
Next we have Louise Chen with Cantor Your line is open hi.
Hi, Thanks for taking my questions here. So I wanted to ask you first off how do you think about or maybe more color on how you think about the pushes and pulls in 2023, there's a lot of moving parts there and then.
And then secondly on your RSV franchise, there seems to be several players attracted development and they are all reported out positive data. So curious how you think about this market playing out over time. Thank you.
Yes.
Safety, what is about the pushes and pulls on that I will ask Angela to complement and are speaking about how we see the RSV. The markets. Clearly 23 is a very very important year for us given the unprecedented number of new launches.
We are going to happen in the next 18 months and most of them will happen in 'twenty three and some beginning of the first quarter of 'twenty before we're launching products not only very big number of them, but.
The only being 10 megawatts 20 billions, excluding the BD bio <unk> and global Blood 20 billion peak sales of our expected 2015 sales we had expected from those.
So it's a very very big number.
It's very important for us to do as well in addition, so clear.
It will.
Bringing our corporate business will be a significant boost for our non core business.
Now when you move to Covid, we expect the industry will be a transition year.
With.
Likely in the U S moving from.
Government model into our commercial model for <unk>.
Our vaccines and therapeutics or the timing is not certain so we are ready to do it a soft but we'll.
We will be faced over the years and it likely will not be the same for extraordinary bar commented method.
Clearly also there will be some that will have to be deployed in 'twenty, three and clear will be new price dynamics. As we are moving to 2030, so probably there will be a little bit more barrels of transition here in 2003 until that will be established into more like a flu volume stifle for market, but of course with different price points and different severity of their disease.
Without the will bring both therapeutic and vaccine into a multibillion dollar franchise, but we are not going to predict now.
The number for the year, so out, but we will try to be as.
Accurate as possible for our 'twenty three numbers when we will provide guidance now Andre anything to add on the <unk>.
A lot of the weight of the new launches and thanks Josh.
One of them, which is going to be the RSV maternal.
In the Gulf.
Well, we're extremely excited about both.
Adult vaccine as well as the maternal vaccine first and foremost because it is in the sweet spot of what Pfizer does respiratory are excellent we had a lot of experience at this.
Created through the legacy of our pneumococcal franchise and the strength, we have there, but also recently from community.
I'll also add that Pfizer is the only company.
That has both the adult vaccine as well as the maternal vaccine.
It really does fit extremely well into our existing commercial footprint.
These are large populations both the adult as well as maternal let me just start with adult and just sort of give you characterized that a bit.
61 million 65 year olds.
<unk>.
Eligible.
For this explanation.
Actually a quite a devastating disease the hospital costs from R&D for adults is over $1 2 billion. It is also underreported and Underdiagnosed and so we have a really great opportunity here to drive awareness of this disease, but also to use the commercial footprint that we already have.
And to create awareness to create education and to bring this vaccine to those who need it.
Equally in the maternal stake.
Overstating disease, most of the mortality and morbidity in infants that are under six months old and <unk>.
That are pre term.
102000 deaths.
Lidar, resulting from infants.
Infections RFP. So again, we see a tremendous opportunity to make a different Tim as you know through the work that we've done on <unk>, we have a tremendous legacy in pediatric.
And vaccines and so that.
That coupled with our strength in women's health and the commercial footprint, we have there as well is going to be perfectly suited for us to launch the maternal RSV vaccine and so on bringing all of this together I think that we have we have the scientific knowledge, we have the technology, we have the relationships.
The vaccinated in the sights of vaccinations will also very well versed in our.
In outlet.
And I work with the vaccine technical committees around the world in bringing together, our broad recommendation, which we believe is what's going to give us access to many many infants as well as adults to lend to these two tremendous breakthroughs. So I think we have the best in class capabilities to do a great job with this respiratory portfolio.
Well Angela I agree with you.
Operator next caller please.
Next we have Steve Scala with Cowen Your line is open.
Thank you I have three questions, but they're all short first what impact on RSV associated infant hospitalization did Pfizer C. In the phase III Metis trial.
Second can you tell us what <unk> sales were in Q3, I know you didn't own bio Haven in Q3, but you likely know the number and then lastly, all things considered is it unrealistic to think that commonality plus tax loaded sales could be as much as $15 billion in 2030.
Yes.
Thank you very much micro what about the RSV data.
Thank you for the question. So as you have seen in our press release, we reported it all very impressive data.
And.
Two separate primary endpoints that were independent.
Sufficient to keep one for filing and two our privilege.
Encouragement, we hit strongly on the most import them.
And that was defined as severe medically attended lower tract respiratory infections, where we had close to 82% fixing efficacy.
That is defined by clinical features such as the rate in distress the brisk duration oxy.
She'll levels et cetera in the shooter Ram and will include patients whether they are hospitalized linoleum.
Later release date on secondary endpoints that include hospitalization. When you look at these dramatic effects on the severe.
Infections.
It seems very reasonable too.
Project that we will have a dramatic impact in lowering hospitalizations and probably talking about tens of thousands what's the limitations in U S that may not happen.
<unk> is vaccine it's used to vaccinate baton.
Prior to.
Delivering this year.
Appropriately studies in this vaccination. So we're very encouraged and optimistic about that type of value.
Thank you. Thank you and Michael before I turn to Dave to answer the question about the sales of metrics in the third quarter, Let me make a comment on <unk> being explored within the franchise clearly we said that it will provide us with big sort of what we expect to be the saves for next year. Now you are asking about the year 2030, which have been more.
Solvency and but also the way you're asking the question is it unthinkable is it unreasonable to think that we could have a 15 billion franchise well taken but it is 55 right now it's not unreasonable to think that in here 20 therapy could be <unk>, but it's not clear, but it will be that so but.
It depends on.
Iverson colleague behaves.
And on <unk>.
It will become a stand our practice to vaccinate together with flu if it was a combination of productivity, but will enhance this direction.
So I think it's a little bit too early but which are not.
Unreasonable thing given that where we are right now no.
Talking about domestic sales, yes, Steve This is Dave as you said, we didn't own the business last quarter, but maybe just a little bit of color on how the products performing if you look at the volume last year or last quarter, rather Q3, maybe.
Share it to last year, it's about a 45% growth rate in Europe in year over year script volume and then if you look at it sequentially, which I think is really important we saw about a 16% growth rate sequentially Q2 going into Q3. So I think this shows the promise of this product number one and number two I think.
Once we get it now that we have it in the hands of our field force and into our primary care and of course, we can really.
Maximize the value of this needed medicine into the patient population here in the U S and abroad.
Thank you very much let's go operator to the next call.
Okay.
Our next question will come from Robyn <unk> with <unk> Securities. Your line is open.
Great. Thanks for taking my question.
On <unk> I was just.
I'm sure you saw the recent publication, citing how many people have died from not even getting an antiviral can you talk a little bit about the efforts, you're making to educate physicians to get the ground then and do you think we'll ever get to a point where people will be more comfortable doctors will be more comfortable taking it given.
All the news around the tax law.
Rebound and second question can you talk a little bit about the opportunity for vitiligo and alopecia and your pipeline and when should we hear the next rehab.
Thank you very much both questions I think can be answer very nicely by Angela.
Well thank you for the question.
Maybe just talk a little bit about pets, Logan and how that's been going I mean first and foremost we are under an EUA.
So that means that we are working hand in hand with the U S. Government ensure that we are providing the education to to the public.
The U S government and the state governments I think have created a tremendous amount of education already.
Using public service announcement in public campaign and equally we have provided education to all the potential.
Prescribed as Opex loaded so do you think about where we are today over 500000 physicians have written <unk> loaded and.
What you have in addition to that is.
<unk> that we provided not only too.
Doctors that also to pharmacists.
Trained over 80000 pharmacists.
And in terms of how to write backs logo and so I think the education is is really firing off both at a prescriber level, but also at a consumer level, where we have lift again also closely with state governments and local governments to ensure that we're providing the right amount of education.
We'll say that.
The test to treat sites that the government has stood up federally.
Now 27000 of those around the country have also been great sources of education full tax loaded so I think that is.
Frankly, I think it's going well I think that we're continuing to do more in anticipation of the fall.
But the fact that you've had 500000 physicians write the tax law that already is a great indicator of.
The confidence with this and the fact that probably the one the one most important area of education that we need to continue to.
To emphasize its just who the eligible people full tax Logan.
And actually if you look at the definition that the CDC provides and they are 22 risk factors, so who should be eligible and they include.
Those are over 65 rite AIDS related risks, but equally risks such as mental health illness risks such as.
In active lifestyle, which that you may not be aware of and so I think that that's really where we want to focus now to me this fall.
And what they bought the <unk>.
I think we're really excited about these new these new indications will be listed nib I.
I think.
Probably the main theme here is that they are not effectively on any treatments for these diseases.
Very serious inflammatory conditions today, so huge unmet need and huge.
And just.
A place where theres just no options today. So the fact that we're able to bring.
<unk>.
Treatment like this to market I think we'll have tremendous uptake by patients who up to now just are left with no options and William can you. Please address it a little bit of Easter about.
Rebounds look very well okay.
Well, Michael I already mentioned that we gave updated data from our epic HR study on the effective <unk> versus placebo in patients with high risk.
For COVID-19, and we had additional endpoints there, which we showed 100% decrease in ICU admissions of 100% decrease in mechanical ventilation among hospitalized patients, 100%, who got that delivered with DC to home versus 53% placebo.
At 82% reduction in oxygen support 86% reduction in COVID-19 related hospitalization, 89% reduction in mean days hospitalized versus 100 patients and also 73% reduction in any COVID-19 related medical visit.
Importantly, we also showed sustained time to symptom alleviation and sustained time to symptom resolution of an impact of two to three days of absolute versus placebo.
But most importantly about rebound theres been several studies recently that have shown actually that rebound occurs with.
Covid in General for example, there was a recent publication of 158 patients and patients who got placebo with Covid and actually a third of those had recurrent symptoms after.
Resolution of their symptoms, suggesting that it's been a phenomenon associated with COVID-19 and notwithstanding that.
Importantly, we also haven't seen any evidence of resistance that is clinically meaningful.
With antibodies for example, we have seen that you get also can get symptom rebound, but that is associated with assistance. So again tech service at associated resistance, but the antibodies are so we feel very confident that <unk> has a significant impact in the bowl against Goldman. Thank you William Operator, Mexico. Please.
Next we have Andrew Baum with Citi. Your line is open.
Thank you couple of questions Firstly as it relates to the maternal RSV vaccine could you talk about reinvestment coverage in the U S. I'm, assuming you'll get in they sit recommendation and therefore there'll be zero out of pocket, which may differentiate versus the monoclonal and I'm sure on a cost basis that will be material.
And then secondly could you talk to your assets with your greater with Venus and lights at the evolving data on sets thinking about astra's recent positive trial and then the <unk> subgroup do you believe that this is a function of finding the right patient population at the right stage of disease, rather than the <unk>.
<unk> risk to development of Utah casually. Thank you.
Andrew.
Finally, let me give you the first answer yes, you are right as long as the product is recommended by CVC I do believe will be vital for efficacy will be recommended but is zero copay irrelevant of the insurance if it was commercial or if it is Bob.
Very obligation is zero co pay from the payers when they have to cover it.
Michael.
The arena has molecules.
Thank you for asking clearly we've seen that the two factors that will separate out.
The good drugs from the less good in this class of Degraders, and we think that protect which is the mechanistic name of the $4. Seven one is more effective in down regulating the estrogen receptor and selecting the right patients compared to standard of care that includes select and pace.
<unk> that type of estrogen receptor mutations and need more powerful drugs and it's related to the property of the drug itself. We look forward to advance that provides with arenas to pivotal studies in the relatively near future and also to soon reveal to you a lot of progress we have in our breast <unk>.
So fem charges, including the CDK four drug and that may be part of what we consider to share in December at the investor update on launches the next waves.
Micro in other regions, where our brand is a great event operator can we go to the next caller. Please.
Next we have <unk> with BMO capital markets. Your line is open.
Hi, guys. Thank you so much for taking my question and congrats on the progress two questions for me on BD I wanted to be brief here, but can you talk about what other therapeutic areas you might want to explore I know you're in neurology with bio haven't nominal non malignant hematology with GBT and of course inflammation would you consider adding oncology and on the same lines.
Albert in some previous comments ahead of this call you had mentioned going alone with some of your mrna technologies what applications of mrna do you see outside of Covid personalized cancer vaccines, an area that you would explore.
Thank you, maybe I'll pass back to EMEA.
I mean, thanks for the question as far as our therapeutic areas of focus.
As I mentioned before in our priorities. Our focus is on where we can make a difference and shape the science and the good news is we actually have distinctive capabilities across many different therapeutic areas. So you've seen us active in internal medicine anti infectives.
Hi.
And certainly oncology and our focus is going to be on where we have breakthrough science.
And the potential to shape it.
And we feel very good about the breadth of our scientific capabilities to give us lots of flexibility to work in different Tas.
Bank of America.
Operator, well go next call. Please.
Next we have.
Alright.
I don't know if I got home zone Kelcey, just one second.
We didn't answer of the mrna and how do we think about it Michael yes.
I'm excited to share with broadening the platform.
Heard about it.
One of the mrna flu vaccine successfully to the next stages.
Mentioned plants that the ongoing to combine it with COVID-19 vaccine to build more broader respiratory vaccine with.
Sure.
<unk> improved convenience in single administration single patient visits.
We are on our way too.
Two the phase one study together with Boeing takes on our shingles vaccine that really aim to deliver the power of the mrna, but remove what is seen as a pretty significant.
We execute with.
Recognition of the current adjuvant that vaccine we're looking at several other mrna vaccine that we will sharing profit time, but also that you briefly alluded to we have made progress in our alliance with beam to.
Really densify the first type of candidates that will move forward to genetic medicine in.
Some of the important rare diseases and we're looking at application Seth.
Seth in areas of in vivo cancer medications, where we think this technology can be more successful.
Compared to the past of accounts vaccines. Thank you very much the micra now operator, we can go through the next 12. Please.
Our next is Mohit Bansal with Wells Fargo. Your line is open.
Great. Thanks for taking my question I almost want to block, but when you got it but this is not the cost side.
Just kidding.
So.
On Odyssey.
On the Odyssey vaccine side.
I mean, so congrats on the data and maternal vaccine. My question is some of this has a VAT.
And antibody, which you can get to.
In fact directly and it shows good result.
In Europe opinion.
I mean, the strategy that they couldnt run strategy.
Humanized.
Moms expecting moms persons in FEMSA rapidly how do you think about the end market shaking up shaking out eventually thank you.
Yes, I'm, sorry, I just wanted to say, how we can compete potentially with an antibody in infants.
I mean first of all if you if you look at where the most.
Most of the morbidity and mortality is happening it's really at the under six months.
Right in that age group and also with preterm babies and so you really need that protection from day, one and I think that that's where that's that's the way we believe our differentiation is.
From that literally from the moment you have protection and you have duration of protection throughout the six months, which is what we've shown in our clinical trials. So I think while there I mean, obviously, it's great to have many different options I think that the option that we have with our vaccine is truly a unique one and one that plays well to do the.
With the intense.
Thank you very much and of course, Andrew made thanks, So deploying what it seems you do not federal base.
Antibodies are quite expensive and you do have to cooperate so let's move to the next.
Next question please.
Next we have Tim Anderson with Wolfe Research your line is open.
Oh, Hi, this is Brian on for Tim I, just two from US what is pfizer's current level of interest in Alzheimer's disease, and do you think there are compelling business development opportunities in the market or with the efforts likely be homegrown.
And then second on <unk> and the competition.
I'm wondering if you can opine on merck's strategy, but just bifurcate the market between peds and adults and have a product tailored to each segment.
They have strange in each and they will be going head to head against INR. They set a tailored approach is better than a one size fits all approach, which is what prep erez just wanted to get your thoughts on that.
Thank you very much clearly as you know Pfizer had to externalize their near science portfolio and we have created a company that it's worth talking about Oxford, and we have a very significant equity over there.
We are monitoring all science is evolving.
Currently there are a few things that are happening right now.
I'm not referring only to the positive data for one started about the just so I'm more referring to earlier science, but these are hedging seems to cover high promising for more most meaningful clinical results. So we are monitoring.
Often but if we think that there is a good opportunity we may re examine entering the reason why we exited we exited because we failed the sciences.
Bye bye.
Now I will move it to Angela to answer your second question.
We're really proud of our pneumococcal vaccine franchise.
I wanted to begin with just talking about the great successes that prep not 'twenty has had.
Since its launch and even though it's competing with with other with another pneumococcal other pneumococcal vaccines, we have a 95% market share we have 97% formulary access.
And we just recently had an updated AC IP recommendation that is going to enable <unk> to be used for catch up in this those are about 65, plus as well as 65.
And so I think that that is a great demonstration of the leadership and the legacy that Pfizer has a pneumococcal vaccines respiratory vaccine and a tremendous relationships and knowledge that we have in the space.
Equally that plays out in the pediatric space.
So.
Even though we are and were obviously anticipating the launch of <unk>.
<unk> not 20.
But in the meantime, <unk> 13 is competing really well with with.
With the PCB 15.
And I think that the.
The relationships that we have the deep trust and knowledge that physicians have of the pneumococcal vaccine and is really standing it's really helping us competitively and I think that is great anticipation for the five additional stereotypes that youre going to be able to get with <unk>.
Over 15 in the pediatric space. So I think all in all we are off to an extremely strong start and we look forward to bringing on next vaccine to the market. Okay. Thank you very very much Angela.
Next question please.
Next we have Chris Schott with Jpmorgan. Your line is open.
Thanks, so much I shouldnt kind of a qualitative question on how to think about Opex dynamics going forward. It seems like we've seen some upward bias and spend at the company, which is kind of coincide with the ramp in Covid sales I guess, if we're in a position where that COVID-19 market resets for transition past. The pandemic is there an opportunity or should we think about.
A pullback in opex spend associated with that.
Or should we think about this as more normalized levels of spend given all of these growth initiatives that you're highlighting in investing behind at this point. Thanks, so much.
Thank you Chris Nice question anchor our new CFO clearly has views on this so Dave what do you think well Chris Good question listen before getting into there's probably a little too early for guidance for 'twenty three but my expectation is that they would not be a pullback in expenses I think if anything what we.
We're fortunate to have is a very robust launch schedule over the next 18 months and we're really focused on investing to make sure that those launches are extremely successful in these medicines get in the hands of patients pretty quickly and so if anything our focus is to get behind these launches make sure that we are.
Keep them flawlessly and that we see the ramp up and drive our sales performance, particularly in the 2025 to 2030 timeframe.
Thank you very much Dave.
Operator next call. Please.
Thanks, Geoff Meacham with Bank of America. Your line is open.
Hey, guys. Good morning, and thanks for the question just had a few this slide on long term growth is really helpful. On the $20 billion on slide nine that you guys have highlighted can you talk to the long term contribution that is not COVID-19 I know theres. Some theres a long term piece for COVID-19, but most investors are focused on kind of the non <unk>.
Covid drivers.
And then looking to next year, when we'll have many biosimilar launching for Humira.
How much of market disruption do you think we'll see from higher by a similar volumes and Payor preferences I'm thinking.
About the effect on.
So bingo and then the trials the mob launched specifically, but also zelle Jameson intellectual thank you.
Yes.
Angela to answer the second question on the first one maybe I can give some clarification from the 20 billion can recover.
Revenues from new launches. So this is our estimate for 2000 therapy, new launches that are happening either stopped it in 'twenty two it shipping for example is there because it started.
And then we are adding claims or are about to happen and we have the lease in the appendix.
This list, excluding <unk>, which we do not count over there we count on the previews, Bob we're incredibly 25 billion of revenues.
Summing to $20 billion and our expectation just to clarify. This does not include Colby. This is excluding coffee, excluding new things, but may contract profit, excluding new things that may come in Antivirals audio vaccines or combination of extremes annual VAT.
Part of that well in the other pipeline, which are things that.
Not in the EMEA EMEA shutdown.
There are things that were launched after the 18 months period, all the way through.
Clearly a lot of these things may be on the.
Unknown to you yet, but among the things that they are going to invest would be included over there should be that <unk> should be ami combinations between flu and COVID-19 or are is really should be or in terms of our own b.
Ann.
The line vaccine Servier Venus should be the gene therapies.
With all of that.
Should the accounts towards.
But the bar, but we haven't quantified that.
Yet publicly of course, you know what do you expect ourselves. Thank you very much now underway.
Okay.
Okay.
Our signals yet.
So the way to think about it is the biologic market and the oral market is the way we think about it is that it's different and the way. The reason I say that is because there is if you look at the treatment algorithms and and how the biologics are used and how the orders are used.
You take Xeljanz as an example, right clearly Dan the label says that you have to you have to have used it to anti TNF before you move on to an oral <unk> and oral JAK.
So I don't think that the competition is across biologics with oral <unk> I think the competition is literally with Humira biosimilar of Humira and <unk> and then the oral <unk> have their role.
Xeljanz is one example, I'll use it RASM odd is another example of the benefit of this is that.
Do you have an oral and oral therapy that actually can be used early align and actually pre biologic. So again there.
<unk>.
The different lines of treatment and the fact that I think they are a distinct places where you would use an oral in a distinct place where you would use a biologic and I don't think thats the cross sell that we're having.
Having a little bit later, hopefully more questions. So we try to make something very quickly operator next question.
Next is Karen Flynn with Morgan Stanley Your line is open.
Thanks for taking the questions I was just wondering on <unk>. It looks like there's going to be some doses remaining on the current U S contract as we head into 2023. So just maybe I know you talked about how coal menotti would work as we move to a commercial market, but maybe just help us think about how.
That will work here in the U S. As we transition out of the pandemic here and then second question I had is just any more detail you can share on the prep and our data in peds regarding.
Serotype coverage I know that was a question that came out post the phase III data. Thanks, so much.
Okay very quickly on the explore but it is very different than what is happening with the vaccine that will be a transition period, we will have to announce things as price then we'll have to work with the U S government to transition so that the.
When they stopped distributing go better.
Uh huh.
Baird.
Good.
We wouldn't let's say stock.
Assuming this transition so the market always.
Carbon, but we will give more details given these dynamics what province, and when this happens.
The transition.
Our next.
The guidance for next year micro anything you have to say on the average just very brief that we have had a positive start is in USD plus one schedule European Union, plus one of either four or three doses, which is the toddler complete schedule, we covered 20 <unk>.
In U S and 19 in the U S.
But the totality of data across all end points. We believe clearly speaks to that this is an important vaccine that adds coverage.
Likely going to be the vaccine in.
In the near term and for quite many years that have the broadest coverage. Thank you next question. Please.
Next we have Chris <unk> with Goldman Sachs. Your line is open.
Thank you in terms of RSV, if you could share some thoughts in terms of the velocity the uptake that youre expecting is flu a good barometer and how quickly do you think if that's the case that we could possibly reach flu and then with the <unk> in the previous owner's hands. There were additional opportunities I believe comes disease data.
Phase two atopic dermatitis phase III, where originally in the timelines for calendar 2022, when we get some insights on that.
Those clinical programs. Thanks.
Yes, I will ask.
Actually before the clinical programs are willing to speak a little bit about yes sure for Trustmark, we have nothing new to update at this time Chris.
Alright, and then how does the I would say clearly we think that it could become like flu like I think all respiratory disease eventually will will.
However coverage like we've had right now in Peru. The question is how often that we operate in and that will depend on several factors.
<unk> of course of all of the people and their physicians, but also the availability of our combination programs and products.
<unk> significantly bring all three of them together RSV globally.
Flu.
The next question please.
Next we have Umar Ross <unk> with Evercore ISI. Your line is open.
Guys. Thanks for taking my question I wanted to ask two questions on pricing today, if I may perhaps first one.
I know the Covid vaccine repricing was a very bold decision and I understand the dynamics around the value proposition the pandemic versus endemic area pricing et cetera, but I think the sheer magnitude of the increase is making a lot of investors ask questions around ESG implications.
Any political blowback et cetera, I'm just curious how you guys thought about this very important decision.
And how youre thinking about the expectation on net pricing and then separately on <unk> I know you're running a 10 day trial versus the five day of course. That's currently approved does that mean <unk> will effectively become two X. The price once a 10 day courses approved thank you very much.
Yes, I can answer both of them look I think what was very Bolton variety oximetry, Susan we're surprised with explorer.
At the very very very low price clearly surprised us.
Okay.
The vaccine at the very very low priced VAT was the right thing to do and we didn't we maintained VAT.
Yes.
Now we are coming to the end of this period, and that's where I'm moving to very different product, which is very different.
Presentations, which are malware moving to single instead of mass viral.
The dose vial.
We are pricing their vaccine according to the cost effectiveness and cost effectiveness.
Over the over the current vaccines waive up to CVC ease or is pricing. It this way way way.
Below what surprises I think I've said that frankly.
Perfect.
Also keep in mind, but.
People will not see any difference in the system would get the benefit of cost effective products and the people who are concerned with because there's a copay.
On the <unk>.
It's too early to speak we haven't announced any price.
And we do not know.
What will be the outcome of the studies or are the outcome of it.
Cautious about discussing following exploring.
So now let's thank you very much assortments, so maybe we move to the last question.
Our last question will come from David Risinger with SBB Securities.
Yes, thanks very much. So my two questions are regarding the core growth, which was 2% operationally in the third quarter could you talk about.
What you are assuming and how we should think about growth prospects in the future specifically in the fourth quarter since you've guided to that in your updated.
Guidance.
And then second could you provide an update and I might've missed this.
I did I apologize, but could you provide an update on your next gen oral antiviral for Covid. Thank you.
Thank you want on the 2% of restaurant.
Excluding corporate.
Just to make a clarification.
If you exclude also the contract manufacturing business about to be forever, but we're certainly COVID-19 related because very increased revenues last year, because we were a contract manufacturing for volume territories, but we don't have to do now because biotech to cover for verity towards that ultimate in your factory.
The growth was 4%.
In our pharmaceutical business, excluding corporate and excluding this piece of contract manufacturing.
Based on what you expect to be.
The growth trajectory.
Well you know we've talked about.
Five year, CAGR right to be 6% and.
Just I want to reiterate that that is exactly the track that we're on.
Every year does not necessarily have to look identical but over the five year period, we're absolutely confident that we're going to develop we're going to deliver the 6% CAGR.
Alright, so thank you very much.
I think we are.
To bring our call to a close.
Please don't forget to ask territory went on December 12, we will provide details about our very important new product launches in the next 18 months and some of our most important pipeline potential new medicines and vaccines. Thank you for joining us today have a great rest of your day.
Ladies and gentlemen, this does conclude todays earnings call and we appreciate your participation you may now disconnect.
[music].
Okay.
Okay.
Okay.
Okay.
Okay.
Okay.
Yes.
No.
[music] platform.
Scott.
[music].
Okay.
Okay.
Thank you.
[music].
Sure.
Okay.
[music].
Yes.
Okay.
Okay.
[music].
Yes.
[music].
Yes.
[music].